Archives of Neuroscience

Published by: Kowsar

Recombinant Tissue Plasminogen Activator Administration in Patients With Cerebrovascular Accident; A Case Series

Hosein Delavar Kasmaei 1 , Alireza Baratloo 2 , * , Zahra Nasiri 1 , Maryam Soleymani 1 and Maryam Oraee Yazdani 3
Authors Information
1 Department of Neurology, Shohadaye Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 Department of Emergency Medicine, Shohadaye Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
3 Department of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Article information
  • Archives of Neuroscience: April 01, 2015, 2 (2); e23315
  • Published Online: April 1, 2015
  • Article Type: Research Article
  • Received: September 7, 2014
  • Revised: October 8, 2014
  • Accepted: October 15, 2014
  • DOI: 10.5812/archneurosci.23315

To Cite: Delavar Kasmaei H, Baratloo A, Nasiri Z, Soleymani M, Oraee Yazdani M. Recombinant Tissue Plasminogen Activator Administration in Patients With Cerebrovascular Accident; A Case Series, Arch Neurosci. 2015 ; 2(2):e23315. doi: 10.5812/archneurosci.23315.

Abstract
Copyright © 2015, Tehran University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet. 2008; 371(9624): 1612-23[DOI][PubMed]
  • 2. Durai Pandian J, Padma V, Vijaya P, Sylaja PN, Murthy JM. Stroke and thrombolysis in developing countries. Int J Stroke. 2007; 2(1): 17-26[DOI][PubMed]
  • 3. Ghandehari K. Barriers of thrombolysis therapy in developing countries. Stroke Res Treat. 2011; 2011: 686797[DOI][PubMed]
  • 4. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol. 2009; 8(4): 355-69[DOI][PubMed]
  • 5. Tosta ED, Rebello LC, Almeida SS, Neiva MS. Treatment of ischemic stroke with r-tPA: implementation challenges in a tertiary hospital in Brazil. Arq Neuropsiquiatr. 2014; 72(5): 368-72[PubMed]
  • 6. Ranklev E, Fletcher R. Anaesthetic management of the malignant hyperthermia susceptible parturient. Can J Anaesth. 1987; 34(1): 106[DOI][PubMed]
  • 7. Kent DM, Price LL, Ringleb P, Hill MD, Selker HP. Sex-based differences in response to recombinant tissue plasminogen activator in acute ischemic stroke: a pooled analysis of randomized clinical trials. Stroke. 2005; 36(1): 62-5[DOI][PubMed]
  • 8. Lai CC, Hu CJ. A left MCA territory infarction during intravenous recombinant tissue plasminogen activator therapy for right MCA territory ischaemic stroke. Emerg Med J. 2006; 23(2)[DOI][PubMed]
  • 9. Li Y, Margraf J, Kluck B, Jenny D, Castaldo J. Thrombolytic therapy for ischemic stroke secondary to paradoxical embolism in pregnancy: a case report and literature review. Neurologist. 2012; 18(1): 44-8[DOI][PubMed]
  • 10. Jauch EC, Saver JL, Adams HP, Jr., Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013; 44(3): 870-947[DOI][PubMed]
  • 11. Albers GW. Expanding the window for thrombolytic therapy in acute stroke. The potential role of acute MRI for patient selection. Stroke. 1999; 30(10): 2230-7[PubMed]
  • 12. Arakawa S, Wright PM, Koga M, Phan TG, Reutens DC, Lim I, et al. Ischemic thresholds for gray and white matter: a diffusion and perfusion magnetic resonance study. Stroke. 2006; 37(5): 1211-6[DOI][PubMed]
  • 13. Gladstone DJ, Black SE. Update on intravenous tissue plasminogen activator for acute stroke: from clinical trials to clinical practice. CMAJ. 2001; 165(3): 311-7[PubMed]
  • 14. Graham GD. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke. 2003; 34(12): 2847-50[DOI][PubMed]
  • 15. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000; 283(9): 1145-50[PubMed]
  • 16. Mullen MT, Pisapia JM, Tilwa S, Messe SR, Stein SC. Systematic review of outcome after ischemic stroke due to anterior circulation occlusion treated with intravenous, intra-arterial, or combined intravenous+intra-arterial thrombolysis. Stroke. 2012; 43(9): 2350-5[DOI][PubMed]
  • 17. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010; 375(9727): 1695-703[DOI][PubMed]
  • 18. Ramaiah SS, Yan B. Low-dose tissue plasminogen activator and standard-dose tissue plasminogen activator in acute ischemic stroke in Asian populations: a review. Cerebrovasc Dis. 2013; 36(3): 161-6[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments